<DOC>
	<DOCNO>NCT01086982</DOCNO>
	<brief_summary>Check pharmacodynamics drug octreotide acetate LAR 30 mg import distributed Chemical Laboratory Pharmaceutical Bergamo Ltda . compare drug Sandostatin LAR ® ( octreotide acetate 30 mg ) manufacture Novartis Biociências S / A , use activity analysis growth hormone ( GH ) growth factor insulin-like 1 ( IGF-1 ) single dose drug patient acromegaly</brief_summary>
	<brief_title>Pharmacodynamics Of Product Octreotide Acetate Lar 30 Mg , Imported And Distributed By The Laboratory Chemical Pharmaceutical Bergamo Ltda. , Compared To Product Sandostatin LAR ® ( Octreotide Acetate LAR ) 30 MG Manufactured By Novartis Biosciences S / A .</brief_title>
	<detailed_description>Secondly , observe safety ( tolerability ) clinical patient compare clinical laboratory parameter study incidence adverse event single dose</detailed_description>
	<mesh_term>Acromegaly</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>Accept Terms Consent ; age 18 , regardless sex ; Patients acromegaly present GH level ≥ 2.5 ng / mL suppression GH level less 1 ng / mL tolerance test glucose IGFI level age sex ; Patients undergo hypophysectomy follow radiotherapy keep níves increase GH IGFI ; Patients wait hypophysectomy increase level GH IGFI Have participate experimental study ingest drug trial within six month prior start study ; Have make use medication influence result , regular 4 week prior start study use medication week start study ; Have treat somastostatina analog dopamine agonist last 2 month ; Present history myocardial infarction , angina / heart failure ; Patients present calculation gallbladder undergone cholecystectomy ; Pregnant woman nurse ; Patients allergies medicine ; Patients history acute pancreatitis ; Patient alter level amylase</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
</DOC>